CONCORDBIO Concord Biotech Q3 FY26 results (Oct–Dec 2025) and concall
Concord Biotech reported a steady Q3 FY26 with 14% YoY revenue growth, primarily driven by strong API sales. While 9-month revenues saw a 5% decline due to H1 headwinds, management expressed optimism for Q4 and beyond, citing recovering order momentum, WHO GMP certification for its injectable facility, and strategic initiatives like its US subsidiary Stellon Biotech. Profitability was impacted by one-off start-up costs, though core EBITDA margins remained robust.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 13.9%, net profit down 8.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 310 | 244 | 430 | 204 | 247 −20% | 278 +14% |
| EBITDA | 137 | 98 | 190 | 61 | 91 −34% | 102 +4% |
| Net profit | 99 | 74 | 142 | 43 | 63 −36% | 68 −8% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
